Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
60Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $39.68M | $-10.02M | $-4.38 |
| 2024 | $32.46M | $-10.06M | $-168.50 |
| 2023 | $57.53M | $-10.95M | $-1955.00 |
| 2022 | $105.42M | $199.0K | $1062.50 |
| 2021 | $167.74M | $3.10M | $14347.50 |
Social Signal Score
Valuation
OSThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsnewsfilecorp.com·2d ago·Negative
OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma Meeting to occur in mid-September 2026 Interim 3-year Overall Survival data expected early September, 2026 Decisions on appropriate comparator arm to interpret OST-HER2 clinical efficacy, RMAT designation and Rolling Review expected following this meeting Sustained overall survival bene…
View source ↗